Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeurAxis, Inc. (NRXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. NeurAxis is a medical technology company focused on neuromodulation therapies, including its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology and IB-Stim device for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older.
Through this page, users can review current and historical reports such as Form 8-K filings, which NeurAxis uses to announce material events. Recent 8-Ks describe FDA 510(k) clearance for expanded PENFS indications in patients aged 8 years and older, including adults, and outline the significance of this clearance as the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in the adult patient population. Other 8-Ks detail capital markets activity, including an At The Market Offering Agreement under a shelf registration statement on Form S-3, preliminary financial estimates, and the termination of a license and collaboration agreement related to the NSS-2 Bridge device.
Investors can also use this filings page to monitor financing structures and equity programs, such as updates to the at-the-market offering capacity and the adoption of the NeurAxis, Inc. 2025 Employee Stock Purchase Plan. These documents explain how the company may issue common stock, the role of its sales agent, applicable commissions, and share limits under employee purchase arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of new 8-Ks, registration statements, and related exhibits. Real-time updates from EDGAR ensure that new NeurAxis filings appear promptly, while structured access to exhibits, legal opinions, and financial disclosures supports deeper analysis of the company’s regulatory, financing, and operational developments.
Neuraxis, Inc. (NRXS) Form 4 filing shows Director and 10% owner Brian P. Hannasch purchased 355,556 common shares on 07/01/2025 at $2.25 per share, an estimated cash outlay of roughly $0.8 million. The transaction was coded “P” (open-market purchase), executed directly, and lifts Hannasch’s total direct holdings to 1,131,522 shares.
Key take-aways:
- The purchase represents a sizable vote of confidence by a control insider.
- Post-transaction ownership exceeds one million shares, reinforcing alignment with minority shareholders.
- No disposals or derivative transactions were reported.
The filing contains no additional financial data or explanatory notes beyond the standard certification.